Tech Company Financing Transactions
Peptimmune Funding Round
Peptimmune, based in Cambridge, secured $6.3 million from MPM Capital, New Enterprise Associates and Prism VentureWorks.
Transaction Overview
Company Name
Announced On
3/31/2009
Transaction Type
Venture Equity
Amount
$6,349,800
Round
Undisclosed
Investors
MPM Capital (Luke Evnin)
New Enterprise Associates (James Barrett)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
64 Sidney Street 380
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Peptimmune is a clinical stage biotechnology company that is utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Fredric Price
Chief Executive Officer
Thomas Mathers
VP - R & D
Eric Zanelli
VP - Regulatory Affairs
Uday Patel
Browse more venture capital transactions:
Prev: 3/31/2009: Breakpoints venture capital transaction
Next: 3/31/2009: PipelineFX venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs